Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Income: 2020-2025

Historic Net Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $621,000.

  • Xeris Biopharma Holdings' Net Income rose 103.95% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 75.22%. This contributed to the annual value of -$54.8 million for FY2024, which is 11.92% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Net Income of $621,000 as of Q3 2025, which was up 132.21% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Net Income registered a high of $621,000 during Q3 2025, and its lowest value of -$50.8 million during Q4 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Net Income averaged around -$11.6 million, with its median value being -$13.4 million (2023).
  • In the last 5 years, Xeris Biopharma Holdings' Net Income plummeted by 132.37% in 2021 and then soared by 103.95% in 2025.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Net Income stood at -$50.8 million in 2021, then spiked by 74.54% to -$12.9 million in 2022, then declined by 3.56% to -$13.4 million in 2023, then spiked by 61.81% to -$5.1 million in 2024, then skyrocketed by 103.95% to $621,000 in 2025.
  • Its Net Income was $621,000 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.